

20 February 2025

The Directors
Life Healthcare Group Holdings Limited
Oxford Parks
203 Oxford Road
Cnr Eastwood and Oxford Roads
Dunkeld
2196

Dear Sirs


CONSENT LETTER

Life Healthcare Group Holdings Limited ("Life Healthcare") is issuing a circular to its shareholders on or about 4 March 2025 (the "Circular"), regarding a proposed disposal through its wholly owned indirect subsidiary, Life Medical Group Limited, of 100% of the issued share capital of Life Molecular Imaging Limited which, together with its subsidiaries, comprise Life Molecular Imaging to Lantheus Radiopharmaceuticals UK Limited, a wholly owned subsidiary of Lantheus Holdings Inc, which constitutes a category 1 transaction in terms of the JSE Listings Requirements.

Deloitte & Touche, in its capacity as Independent Auditors to Life Healthcare, hereby consents to its name being stated and to the references thereto in the form and context in which it appears in the Circular.

Such consent will not be withdrawn prior to the issue of the Circular.

Yours faithfully

Signed by:


James Welch
Partner
Deloitte & Touche



National Executive: *R Redfearn Chief Executive Officer *GM Berry Chief Operating Officer JW Eshun Managing Director Businesses LN Mahluza Chief People Officer *N Sing Chief Risk Officer AP Theophanides Chief Sustainability Officer *NA le Riche Chief Growth Officer *ML Tshabalala Audit & Assurance AM Babu Consulting TA Odukoya Financial Advisory G Rammego Risk Advisory DI Kubeka Tax & Legal

A full list of partners and directors is available on request * Partner and Registered Auditor

B-BBEE rating: Level 1 contribution in terms of the DTI Generic Scorecard as per the amended Codes of Good Practice

Associate of Deloitte Africa, a Member of Deloitte Touche Tohmatsu Limited